Enspryng

Enspryng

satralizumab

Manufacturer:

Roche

Distributor:

DKSH
Concise Prescribing Info
Contents
Satralizumab
Indications/Uses
Neuromyelitis optica spectrum disorders in adults & adolescents ≥12 yr.
Dosage/Direction for Use
SC Loading dose: 1st three 120 mg once every 2 wk. Maintenance dose: 120 mg every 4 wk.
Contraindications
Special Precautions
Monitor for any signs of infections (eg, fever or chills, cough that does not go away, sore throat, herpes simplex, herpes zoster, skin redness, swelling, tenderness or pain, feeling or being sick, diarrhoea or belly pain). Delay administration or continuation of treatment until infection is controlled. Not to be administered w/ live or live attenuated vaccines (eg, BCG for TB or vaccines against yellow fever) during treatment. Potential increased liver enzymes. Monitor for signs of liver damage (eg, jaundice, dark-colored urine, feeling & being sick, abdominal pain) during or after treatment. Check WBC count before & during treatment. Pregnancy & lactation. Not to be given to childn <12 yr.
Adverse Reactions
Allergic reactions; inj related reactions; headache, joint pain, increased blood lipids, decreased WBC. Feeling stiff, migraine, bradycardia, increased BP, unable to sleep, swelling in lower legs, feet or hands, rash or itching, allergies or hay fever, gastritis including stomach pain & nausea, increased wt, low fibrinogen & platelet levels, high levels of liver enzymes & bilirubin.
Drug Interactions
Concomitant use w/ warfarin, carbamazepine, phenytoin & theophylline.
MIMS Class
Immunosuppressants
ATC Classification
L04AC19 - satralizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Enspryng soln for inj 120 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in